{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:15:49Z","timestamp":1769577349644,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gruppo San Donato Foundation"},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Osteoporosis is characterized by loss of bone mass and susceptibility to fracture. Skeletal effects of teriparatide (TPT) are not persistent after drug withdrawal and sequential therapy with bisphosphonates or denosumab (Dmab) after TPT discontinuation represents a valid option. Here, the two sequential strategies were evaluated in severe osteoporotic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study retrospectively enrolled 56 severe osteoporotic patients who received TPT for 24 months followed by 24 months of zoledronic acid (ZOL) (TPT\u2009+\u2009ZOL) or Dmab (TPT+Dmab). Clinical features, incident fractures, bone mineral density (BMD) measurements, and bone marker profiles were collected. One-way ANOVA analyzed the difference between mean T-scores at baseline, after 24 months of TPT, and after 2 doses of ZOL or after at least 3 doses of Dmab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-three patients received TPT\u2009+\u2009ZOL (19 females, 4 males; median [IR] age, 74.3 [66.9, 78.6] years) and 33 patients received TPT+Dmab (31 females, 2 males; mean [IR] age, 66.6\u2009\u00b1\u200911.3 years). Mean lumbar and hip T-scores were increased after both TPT\u2009+\u2009ZOL and TPT+Dmab (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 vs baseline). The size effects induced by TPT\u2009+\u2009ZOL on the lumbar and hip BMD T-scores were similar to those observed with TPT+Dmab with mean T-scores increases of about 1 and 0.4\u2009SD, respectively. No significant between-group differences were identified. Incident fragility fractures occurred in 3 (13%) patients treated with TPT\u2009+\u2009ZOL and in 5 (15%) patients treated with TPT+Dmab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Sequential TPT\u2009+\u2009ZOL therapy is likely to increase bone mineralization at the lumbar level and to stabilize it at the femoral level, similarly to what obtained with the sequential TPT+Dmab. Both ZOL and Dmab are suggested to be effective sequential treatments after TPT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-023-03431-6","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T05:01:54Z","timestamp":1688446914000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study"],"prefix":"10.1007","volume":"82","author":[{"given":"Giorgia","family":"Dito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Lugaresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Degradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"Guabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Longhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-3175","authenticated-orcid":false,"given":"Sabrina","family":"Corbetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"3431_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/s0140-6736(18)32112-3","volume":"39","author":"JE Compston","year":"2019","unstructured":"J.E. Compston, M.R. McClung, W.D. Leslie, Osteoporosis. Lancet 39, 364\u2013376 (2019). https:\/\/doi.org\/10.1016\/s0140-6736(18)32112-3","journal-title":"Lancet"},{"key":"3431_CR2","unstructured":"European Medicines Agency. Forsteo (teriparatide) - Prescribing Information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/forsteo. (Accessed 23 September 2022)."},{"key":"3431_CR3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/nejm200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med 344, 1434\u20131441 (2001). https:\/\/doi.org\/10.1056\/nejm200105103441904","journal-title":"N. Engl. J. Med"},{"key":"3431_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12020-019-01919-8","volume":"64","author":"N Gua\u00f1abens","year":"2019","unstructured":"N. Gua\u00f1abens, M.J. Moro-\u00c1lvarez, E. Casado, J. Blanch-Rubi\u00f3, C. G\u00f3mez-Alonso, G.M. D\u00edaz-Guerra, J. Del Pino-Montes, C. Valero D\u00edaz de Lamadrid, P. Peris, M. Mu\u00f1oz-Torres, The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. Endocrine 64, 441\u2013455 (2019). https:\/\/doi.org\/10.1007\/s12020-019-01919-8","journal-title":"Endocrine"},{"key":"3431_CR5","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EJE-18-0056","volume":"179","author":"AD Anastasilakis","year":"2018","unstructured":"A.D. Anastasilakis, S.A. Polyzos, P. Makras, Therapy of Endocrine disease: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur. J. Endocrinol. 179, R31\u2013R45 (2018). https:\/\/doi.org\/10.1530\/EJE-18-0056","journal-title":"Eur. J. Endocrinol."},{"key":"3431_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","volume":"35","author":"K Ebina","year":"2017","unstructured":"K. Ebina, J. Hashimoto, M. Kashii, M. Hirao, S. Kaneshiro, T. Noguchi, Y. Tsukamoto, H. Yoshikawa, The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J. Bone Min. Metab. 35, 91\u201398 (2017). https:\/\/doi.org\/10.1007\/s00774-015-0731-x","journal-title":"J. Bone Min. Metab."},{"key":"3431_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bonr.2017.06.001","volume":"7","author":"T Shimizu","year":"2017","unstructured":"T. Shimizu, T. Tanaka, T. Kobayashi, I. Kudo, M. Nakatsugawa, A. Takakura, R. Takao-Kawabata, T. Ishizuya, Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats. Bone Rep. 7, 70\u201382 (2017). https:\/\/doi.org\/10.1016\/j.bonr.2017.06.001","journal-title":"Bone Rep."},{"key":"3431_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.eprac.2021.05.012","volume":"27","author":"T Kocjan","year":"2021","unstructured":"T. Kocjan, A.S. Rajic, A. Janez, G. Vidmar, N. Orehek, J. Marc, B. Ostanek, Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis. Endocr. Pr. 27, 941\u2013947 (2021). https:\/\/doi.org\/10.1016\/j.eprac.2021.05.012","journal-title":"Endocr. Pr."},{"key":"3431_CR9","first-page":"749","volume":"81","author":"MA Sarli","year":"2021","unstructured":"M.A. Sarli, C. Habib, M.B. Zanchetta, Which is the best antiresorptive treatment after finishing teriparatide? Med. (B. Aires) 81, 749\u2013753 (2021)","journal-title":"Med. (B. Aires)"},{"key":"3431_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1359\/JBMR.041115.","volume":"20","author":"N Binkley","year":"2005","unstructured":"N. Binkley, G.M. Kiebzak, E.M. Lewiecki, D. Krueger, R.E. Gangnon, P.D. Miller, J.A. Shepherd, M.K. Drezner, Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J. Bone Min. Res. 20, 195\u2013201 (2005). https:\/\/doi.org\/10.1359\/JBMR.041115.","journal-title":"J. Bone Min. Res."},{"key":"3431_CR11","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"R. Lindsay, W.H. Scheele, R. Neer, G. Pohl, S. Adami, C. Mautalen, J.Y. Reginster, J.J. Stepan, S.L. Myers, B.H. Mitlak, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern Med. 164, 2024\u20132030 (2004). https:\/\/doi.org\/10.1001\/archinte.164.18.2024","journal-title":"Arch. Intern Med."},{"key":"3431_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"J.M. Kaufman, E. Orwoll, S. Goemaere, J. San Martin, A. Hossain, G.P. Dalsky, R. Lindsay, B.H. Mitlak, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510\u2013516 (2005). https:\/\/doi.org\/10.1007\/s00198-004-1713-3","journal-title":"Osteoporos. Int."},{"key":"3431_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"R. Eastell, C.J. Rosen, D.M. Black, A.M. Cheung, M.H. Murad, D. Shoback, Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 104, 1595\u20131622 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3431_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jbm4.10054","volume":"2","author":"R Niimi","year":"2018","unstructured":"R. Niimi, T. Kono, A. Nishihara, M. Hasegawa, T. Kono, A. Sudo, Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial. JBMR 2, 289\u2013294 (2018). https:\/\/doi.org\/10.1002\/jbm4.10054","journal-title":"JBMR"},{"key":"3431_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"B.Z. Leder, J.N. Tsai, A.V. Uihlein, P.M. Wallace, H. Lee, R.M. Neer, S.A. Burnett-Bowie, Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386, 1147\u20131155 (2015). https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03431-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:25:43Z","timestamp":1693211143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03431-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["3431"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03431-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"S.C. received research grants from Gedeon Richter and Sandoz; G.D., M.L., C.D., G.G., and M.L. have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study experimental procedure complied with the principles of the Declaration of Helsinki (1964 and later amendments). No ethic committee approval was required according to the Italian law given the observational design of the study [Ministero della Salute, Attivit\u00e0 dei Comitati Etici Istituiti ai Sensi del Decreto Ministeriale 18 Marzo 1998. CIRCOLARE MINISTERIALE N.6 DEL 2 SETTEMBRE 2002. G.U. n. 214 12 settembre 2002.  (Accessed 19 October 2022)]. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}